Description
Tranexamic acid competitively inhibits activation of plasminogen(via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
Drug Interactions
Estrogens , Thrombolytic drugs.
Indication
Tranexamic acid is indicated for the treatment of: – Hemorrhage or risk of hemorrhage in increased fibrinolysis or fibrinogenolysis.
Precautions:
- Tranexamic acid should not be administered by the intramuscular route.
- Intravenous Injection of tranexamic acid should be given very slowly.
- In case of haematuria from the upper urinary tract, there is a risk for urethral obstruction.
Reviews
There are no reviews yet.